Arteriovenous Malformations Market Trends Reshaping Industry Growth Through 2030
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Arteriovenous Malformations Market Poised To Hit $4.37 Billion By 2030 With A 7.1% CAGR
The arteriovenous malformations market has demonstrated significant expansion in recent years. This market is forecasted to increase from $3.1 billion in 2025 to $3.33 billion by 2026, achieving a compound annual growth rate (CAGR) of 7.3%. Historically, this growth has been primarily driven by advancements in neuroimaging technologies, a rise in clinical awareness concerning AVM conditions, the establishment of specialized neurosurgical centers, the adoption of endovascular embolization techniques, and the general expansion of hospital-based neurological care.
The arteriovenous malformations market size is anticipated to undergo significant expansion over the next few years. It is projected to achieve $4.37 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.1%. This projected growth can be ascribed to a surge in the demand for precision diagnostics, increased investments in neurovascular research, broader adoption of minimally invasive treatments, an intensified focus on personalized treatment planning, and the increasing availability of advanced interventional devices. Prominent trends expected during the forecast period involve the rising uptake of advanced neuroimaging diagnostics, an increase in the utilization of minimally invasive endovascular treatments, a greater emphasis on early and accurate diagnosis, the expansion of multidisciplinary treatment approaches, and enhanced monitoring of post-treatment outcomes.
Get A Free Sample Report With In-Depth Market Insights:
Arteriovenous Malformations Market Growth Momentum: What Factors Are Shaping Demand?
The arteriovenous malformations market is anticipated to grow propelled by the increasing demand for minimally invasive procedures. Minimally invasive procedures involve surgical or therapeutic interventions performed with small incisions or catheter-based techniques, aiming to minimize trauma, shorten recovery periods, and reduce complications. The surge in demand for minimally invasive surgeries is driven by faster recovery times, as these procedures entail smaller incisions, leading to less tissue damage and quicker healing. This allows patients to return to their normal routines more rapidly compared to traditional open surgeries, making them a preferred option for both patients and healthcare providers. Arteriovenous malformations (AVMs) benefit from minimally invasive approaches by enabling advanced techniques such as endovascular embolization, which uses catheters and image guidance to reduce abnormal blood flow without the need for open surgery, resulting in lower risks, quicker recovery times, and improved patient outcomes. For instance, in September 2023, according to the American Society of Plastic Surgeons, a US-based in 2023, a total of 25,442,640 cosmetic minimally invasive procedures were performed, representing an increase from 23,672,269 procedures in 2022. This reflects a 7% growth in minimally invasive treatments for both genders in 2023. Therefore, the escalating demand for minimally invasive procedures is driving the growth of the arteriovenous malformations market.
Arteriovenous Malformations Market Segment Performance And Emerging Opportunities
The arteriovenous malformations market covered in this report is segmented –
1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types
2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis
3) By Treatment: Endovascular Embolization, Neurosurgery
4) By Age Group: Adult Patients, Pediatric Patients
5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users
Subsegments:
1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs
2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs
3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations
4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome
5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas
6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula
7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs
Arteriovenous Malformations Market Trends Redefining Industry Growth
Leading companies in the arteriovenous malformations market are emphasizing technological advancements, such as liquid embolic system procedural sets, to improve treatment processes and patient outcomes. A liquid embolic system procedural set refers to a pre-assembled, sterile kit containing essential components for delivering liquid embolic agents to treat vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set comprises two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system in a single sterilized package, optimizing procedure preparation for managing cerebral arteriovenous malformations (AVMs).
Arteriovenous Malformations Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation
View The Full Arteriovenous Malformations Market Report:
Arteriovenous Malformations Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
